Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma | Zendy

Alexander M.M. Eggermont | Zendy; Christian U. Blank | Zendy; Mario Mandalà | Zendy; Georgina V. Long | Zendy; Victoria Atkinson | Zendy; Stéphane Dalle | Zendy; Andrew Haydon | Zendy; Mikhail Lichinitser | Zendy; Adnan Khattak | Zendy; Matteo S. Carlino | Zendy; Shahneen Sandhu | Zendy; James Larkin | Zendy; Susana Puig | Zendy; Paolo A. Ascierto | Zendy; Piotr Rutkowski | Zendy; Dirk Schadendorf | Zendy; Rutger H.T. Koornstra | Zendy; Leonel F. HernandezAya | Zendy; Michele Maio | Zendy; Alfonsus J.M. van den Eertwegh | Zendy; Jean-Jacques Grob | Zendy; Ralf Gutzmer | Zendy; Rahima Jamal | Zendy; Paul Lorigan | Zendy; Nageatte Ibrahim | Zendy; Sandrine Marréaud | Zendy; Alexander C.J. van Akkooi | Zendy; Stefan Suciu | Zendy; Caroline Robert | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Author(s) -

Alexander M.M. Eggermont,

Christian U. Blank,

Mario Mandalà,

Georgina V. Long,

Victoria Atkinson,

Stéphane Dalle,

Andrew Haydon,

Mikhail Lichinitser,

Adnan Khattak,

Matteo S. Carlino,

Shahneen Sandhu,

James Larkin,

Susana Puig,

Paolo A. Ascierto,

Piotr Rutkowski,

Dirk Schadendorf,

Rutger H.T. Koornstra,

Leonel F. HernandezAya,

Michele Maio,

Alfonsus J.M. van den Eertwegh,

Jean-Jacques Grob,

Ralf Gutzmer,

Rahima Jamal,

Paul Lorigan,

Nageatte Ibrahim,

Sandrine Marréaud,

Alexander C.J. van Akkooi,

Stefan Suciu,

Caroline Robert

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1802357

Subject(s) - pembrolizumab , adjuvant , placebo , stage (stratigraphy) , medicine , melanoma , oncology , cancer research , cancer , biology , immunotherapy , pathology , alternative medicine , paleontology

The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage III melanoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research